Anixa Biosciences (NASDAQ:ANIX) Earns Buy Rating from Analysts at Maxim Group

Maxim Group started coverage on shares of Anixa Biosciences (NASDAQ:ANIX - Get Free Report) in a research note issued to investors on Friday, Marketbeat Ratings reports. The brokerage set a "buy" rating and a $10.00 price target on the stock. Maxim Group's price target indicates a potential upside of 217.46% from the stock's current price.

A number of other equities research analysts also recently weighed in on the company. HC Wainwright reiterated a "buy" rating and issued a $7.00 price target on shares of Anixa Biosciences in a report on Tuesday, February 18th. D. Boral Capital reaffirmed a "buy" rating and issued a $10.00 target price on shares of Anixa Biosciences in a research report on Wednesday, January 22nd.

Anixa Biosciences Price Performance

ANIX traded down $0.05 on Friday, reaching $3.15. The company's stock had a trading volume of 158,646 shares, compared to its average volume of 97,486. Anixa Biosciences has a 1 year low of $2.07 and a 1 year high of $4.20. The business's 50 day moving average is $2.94 and its 200 day moving average is $3.00. The stock has a market cap of $101.42 million, a price-to-earnings ratio of -8.08 and a beta of 0.86.

Anixa Biosciences (NASDAQ:ANIX - Get Free Report) last released its earnings results on Tuesday, March 11th. The company reported ($0.10) EPS for the quarter, meeting the consensus estimate of ($0.10). As a group, research analysts forecast that Anixa Biosciences will post -0.41 earnings per share for the current fiscal year.

Insider Buying and Selling at Anixa Biosciences

In other news, Director Lewis H. Titterton, Jr. bought 10,000 shares of the firm's stock in a transaction that occurred on Friday, January 17th. The stock was acquired at an average price of $2.57 per share, with a total value of $25,700.00. Following the completion of the purchase, the director now directly owns 922,334 shares of the company's stock, valued at $2,370,398.38. This represents a 1.10 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Amit Kumar acquired 43,000 shares of Anixa Biosciences stock in a transaction dated Wednesday, January 15th. The shares were acquired at an average price of $2.23 per share, with a total value of $95,890.00. Following the transaction, the chief executive officer now owns 559,925 shares in the company, valued at approximately $1,248,632.75. This represents a 8.32 % increase in their position. The disclosure for this purchase can be found here. Over the last 90 days, insiders have bought 75,289 shares of company stock worth $177,021. 25.30% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of ANIX. Virtu Financial LLC acquired a new stake in shares of Anixa Biosciences during the third quarter worth $34,000. Millennium Management LLC acquired a new stake in Anixa Biosciences during the 4th quarter worth about $26,000. Renaissance Technologies LLC lifted its stake in Anixa Biosciences by 36.5% during the fourth quarter. Renaissance Technologies LLC now owns 14,573 shares of the company's stock valued at $34,000 after buying an additional 3,900 shares in the last quarter. Prosperity Wealth Management Inc. purchased a new position in shares of Anixa Biosciences in the fourth quarter worth approximately $54,000. Finally, Jane Street Group LLC purchased a new stake in shares of Anixa Biosciences in the 4th quarter valued at approximately $67,000. Institutional investors own 29.13% of the company's stock.

Anixa Biosciences Company Profile

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.